BUZZ-Innovent Biologics rises as regulator approves co's product for cancer treatment

Reuters
01-17
BUZZ-Innovent Biologics rises as regulator approves co's product for cancer treatment

** Shares of Innovent Biologics Inc 1801.HK rise 3.3% to HK$31, on course to snap two consecutive session of decline

** Stock on track for the biggest one-day jump since Dec. 9, 2024; among top 10 gainers in healthcare index .HSCIH, which is up 0.8%

** Innovent says new drug application of limertinib - the third-generation epidermal growth factor receptor tyrosine kinase inhibitor, has received approval by National Medical Products Administration of China (NMPA) for treatment of lung cancer

** Hang Seng Commerce & Industry Index .HSNC and Hang Seng Index .HSI boht slip 0.1%

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10